Peptide Comparison
Vesugen vs Crystagen
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Vesugen and Crystagen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: limited western evidence. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Vesugen | Crystagen | |
|---|---|---|
| Class | Khavinson short peptide bioregulator | Khavinson short peptide bioregulator |
| Drug class | Tissue Repair | Immune |
| Mechanism | Endothelial gene expression modulation | Tissue-specific gene expression in lymphoid/thymic cells; normalizes T-cell and macrophage activity; doubles HSPA1A heat-shock expression and modulates IL-6 |
| Route | Oral | Oral |
| Half-life | Short (minutes) | Short (minutes) |
| Dosage (research) | Oral capsule 1-2x daily | Oral 1-2 capsules daily for 20-30 day courses |
| Evidence tier | Russian Research | Russian Research |
| Research depth | 10 indexed | 36 indexed |
| Availability | Research | Research |
| Reported risks | Limited Western evidence | Limited Western evidence; primarily Russian gerontology literature |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Vesugen or Crystagen?
Vesugen and Crystagen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
What is the difference between Vesugen and Crystagen?
Vesugen is classed as Khavinson short peptide bioregulator; Crystagen is classed as Khavinson short peptide bioregulator. Reported mechanism: Vesugen, Endothelial gene expression modulation; Crystagen, Tissue-specific gene expression in lymphoid/thymic cells; normalizes T-cell and macrophage activity; doubles HSPA1A heat-shock expression and modulates IL-6. Reported half-life: Vesugen, Short (minutes); Crystagen, Short (minutes). Routes in published studies: Vesugen, Oral; Crystagen, Oral.
Which has stronger evidence, Vesugen or Crystagen?
Vesugen and Crystagen sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Vesugen is graded Russian Research, with 2 cited sources on its reference page and 10 indexed studies. Crystagen is graded Russian Research, with 2 cited sources on its reference page and 36 indexed studies.
Which is more accessible, Vesugen or Crystagen?
Neither Vesugen nor Crystagen is an FDA-approved drug. Catalog status: Vesugen, Research; Crystagen, Research.
Are Vesugen and Crystagen ever combined?
Vesugen and Crystagen appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…